Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia

Hospices Civils de Lyon47 enrolled

Overview

Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained virological response rates (SVR12) above 90%. The objective of this study was to investigate the impact of DAA therapy on cryoglobulin clearance in patients with HCV-associated MC.

We focused on HCV patients with or without HIV with MC who had at least one cryoglobulin level assessment before and after DAA therapy and investigated the impact of DAA therapy on cryoglobulin clearance.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hepatitis C, Chronic Mixed Cryoglobulinemia

Interventions

DAA treatmentDRUG

Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hepatitis C virus (HCV) infected patients * symptomatic or asymptomatic mixed cryoglobulinemia * coinfected or not with HIV * treated by direct-acting antiviral (DAA) treatment * at least one cryoglobulin measurement before and after DAA Exclusion Criteria: \-

Locations (1)

Hospices Civils de Lyon - Croix-Rousse Hospital

Lyon, France

Outcomes

Primary Outcomes

Cryoglobulin level at the end of therapy

The primary outcome was the cryoglobulin level at the end of direct-acting antiviral treatment (week 12 or 24 according to treatment duration)

Time frame: End of treatment (12 or 24 weeks)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.